Celltrion announced on the 21st that its consolidated revenue in the second quarter of this year increased by 9.9% compared to the same period last year, amounting to about 961.5 billion won, and its operating profit increased by 234.5% compared to the same period last year, reaching about 242.5 billion won.
Both revenue and operating profit reached an all-time high for the second quarter, with the operating profit margin improving to the 25% range. However, this is based on the company's internally calculated provisional results, and some changes may occur depending on the accounting review.
A company official noted, "Revenue from new products with high profitability expanded in the second quarter, achieving the highest performance ever for this period."
High-revenue products such as the autoimmune disease treatment "Remsima SC" (U.S. product name: Jimpendra), "Uplima", "Steqeyma", and the anticancer drug "Vegzelma" contributed to the expansion of revenue and operating profit. The proportion of high-revenue new products accounted for 53% of total revenue in the second quarter, up from 30% in the same period last year.
Efforts to improve costs also contributed to the expansion of profitability. The company's cost ratio for the second quarter of this year was about 43%, a decrease of approximately 15 percentage points compared to the same period last year (58%) and a decline of 4 percentage points from the previous quarter.
The company plans to sequentially launch four new products in major global markets in the second half of this year. Celltrion expects, "We will also release high-revenue new products in Europe, the U.S., and other regions in the second half, so we anticipate a steeper growth trend compared to the first half," and stated that it aims to continue company-wide efforts for growth.